Insulin resistance alters islet morphology in nondiabetic humans

Diabetes

Volumn 63, Issue 3, 2014, Pages 994-1007

  Mezza, Teresa ^a,b   Muscogiuri, Giovanna ^b   Sorice, Gian Pio ^b   Clemente, Gennaro ^b   Hu, Jiang ^a   Pontecorvi, Alfredo ^b   Holst, Jens J ^c   Giaccari, Andrea ^b,d   Kulkarni, Rohit N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c Capital Region   (Denmark)

^d IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-SECRETING CELLS; HUMANS; HYPERPLASIA; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PANCREATECTOMY;

EID: 84894478069     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1013     Document Type: Article

References (47)

1. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011;378:169-181
2. Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998;47:358-364
3. Brüning JC, Winnay J, Bonner-Weir S, Taylor SI, Accili D, Kahn CR. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 1997;88:561-572
4. Yoon KH, Ko SH, Cho JH, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab 2003;88:2300-2308
5. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52:102-110
6. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest 1988;81: 435-441
7. Saisho Y, Butler AE, Manesso E, Elashoff D, Rizza RA, Butler PC. b-cell mass and turnover in humans: effects of obesity and aging. Diabetes Care 2013;36:111-117
8. Butler AE, Cao-Minh L, Galasso R, et al. Adaptive changes in pancreatic beta cell fractional area and beta cell turnover in human pregnancy. Diabetologia 2010;53:2167-2176
9. Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005;48:2236-2240
10. Giaccari A, Sorice G, Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes-mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis 2009;19:365-377
11. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A. Beta-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001;50(Suppl. 1):S154-S159
12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2013;36(Suppl. 1):S67-S74
13. Muscogiuri G, Sorice GP, Prioletta A, et al. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring) 2010;18:1906-1910
14. Lohman TG, Roche AF, Martorelli R. Anthropometric Standardization Reference Manual. Champaign, IL, Human Kinetics Books, 1988, p. 177
15. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223
16. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801
17. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000;85:3575-3581
18. Traverso LW, Longmire WP Jr. Preservation of the pylorus in pancreaticoduodenectomy a follow-up evaluation. Ann Surg 1980;192:306-310
19. Muscogiuri G, Mezza T, Prioletta A, et al. Removal of duodenum elicits GLP-1 secretion. Diabetes Care 2013;36:1641-1646
20. Schrader H, Menge BA, Breuer TG, et al. Impaired glucose-induced glucagon suppression after partial pancreatectomy. J Clin Endocrinol Metab 2009;94:2857-2863
21. Bonner-Weir S, Deery D, Leahy JL, Weir GC. Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes 1989;38:49-53
22. Kulkarni RN, Holzenberger M, Shih DQ, et al. beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 2002;31:111-115
23. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999;48:2270-2276
24. Norman JT, Bohman RE, Fischmann G, et al. Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasia. Proc Natl Acad Sci U S A 1988;85:6768-6772
25. Studer H, Derwahl M. Mechanisms of nonneoplastic endocrine hyperplasia-a changing concept: a review focused on the thyroid gland. Endocr Rev 1995;16:411-426
26. Kulkarni RN, Brüning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999;96:329-339
27. Assmann A, Hinault C, Kulkarni RN. Growth factor control of pancreatic islet regeneration and function. Pediatr Diabetes 2009;10:14-32
28. Halperin F, Lopez X, Manning R, Kahn CR, Kulkarni RN, Goldfine AB. Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulinresistant humans. Diabetes 2012;61:301-309
29. Meier JJ, Butler AE, Galasso R, Butler PC. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care 2006;29:1554-1559
30. Caballero F, Siniakowicz K, Hollister-Lock J, et al. Birth and death of human b-cells in pancreas from cadaver donors, autopsies, surgical specimens, and islets transplanted into mice. Cell Transplant 2 January 2013 [Epub ahead of print]
31. Folli F, Okada T, Perego C, et al. Altered insulin receptor signalling and b-cell cycle dynamics in type 2 diabetes mellitus. PLoS ONE 2011;6: e28050
32. Gregg BE, Moore PC, Demozay D, et al. Formation of a human b-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab 2012;97:3197-3206
33. Yoneda S, Uno S, Iwahashi H, et al. Predominance of b-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes. J Clin Endocrinol Metab 2013;98:2053-2061
34. Juhl K, Bonner-Weir S, Sharma A. Regenerating pancreatic beta-cells: plasticity of adult pancreatic cells and the feasibility of in-vivo neogenesis. Curr Opin Organ Transplant 2010;15:79-85
35. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci U S A 2010;107:16009-16012
36. Kawamori D, Kurpad AJ, Hu J, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 2009;9:350-361
37. Henquin JC, Rahier J. Pancreatic alpha cell mass in European subjects with type 2 diabetes. Diabetologia 2011;54:1720-1725
38. Guardado-Mendoza R, Jimenez-Ceja L, Majluf-Cruz A, et al. Impact of obesity severity and duration on pancreatic b-and a-cell dynamics in normoglycemic non-human primates. Int J Obes (Lond) 2013;37:1071-1078
39. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic b cell dedifferentiation as a mechanism of diabetic b cell failure. Cell 2012;150:1223-1234
40. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004;36: 747-754
41. Marchetti P, Lupi R, Bugliani M, et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 2012;55:3262-3272
42. Li Y, Cao X, Li LX, Brubaker PL, Edlund H, Drucker DJ. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005;54:482-491
43. Zhu X, Zhou A, Dey A, et al. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc Natl Acad Sci U S A 2002;99:10293-10298
44. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-5158
45. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004;47:806-815
46. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 2003;100:1438-1443
47. Akiyama M, Liew CW, Lu S, et al. X-box binding protein 1 is essential for insulin regulation of pancreatic a-cell function. Diabetes 2013;62:2439-2449